Literature DB >> 29915442

Left ventricular hypertrophy and proteinuria in patients with essential hypertension in Andkhoy, Afghanistan.

Mohammad Shoaib Hamrah1, Mohammad Hassan Hamrah2,3, Hideki Ishii1, Susumu Suzuki1, Mohammad Hussain Hamrah2,4, Ahmad Edris Hamrah2, Ahmad Elias Dahi2, Maimaiti Yisireyili1, Naoaki Kano1, Kyosuke Takeshita5, Mohammad Hashem Hamrah2, Junichi Sakamoto6, Toyoaki Murohara1.   

Abstract

Left ventricular hypertrophy (LVH) and proteinuria are known as independent predictors of cardiovascular death in hypertension. However, LVH and its association with proteinuria have not been investigated in adult hypertensive patients in Afghanistan. The objective of this research was to determine the prevalence of LVH and the correlation between LVH and proteinuria among the Afghan adult hypertensive population visiting an outpatient clinic in Afghanistan. We retrospectively evaluated 789 hypertensive patients (mean age is 56 years and 46% were men) who visited the clinic between December 2014 and August 2016. Patient characteristics and laboratory and clinical findings were recorded. The rate of LVH among hypertensive patients was 54.4%. Patients with proteinuria had a significantly higher LVH percentage compared to those without proteinuria (73.2% versus 55.8%; P<0.001). There was a significant correlation between LVH and proteinuria among hypertensive patients (r=0.182, P<0.001). Based on a multivariate regression analysis, age (odds ratio [OR], 1.04; 95% confidence interval [CI], 1.02-1.05), proteinuria (OR, 1.69; 95% CI, 1.19-2.41), and female sex (OR, 0.09; 95% CI, 0.06-0.13) were significant factors. In conclusion, the prevalence of LVH was more than 50% in the Afghan adult hypertensive population. This study indicates that there is a significant relationship between LVH detected by ECG and the presence of proteinuria among such subjects.

Entities:  

Keywords:  Afghanistan; Andkhoy; hypertensive patients; left ventricular hypertrophy; proteinuria

Year:  2018        PMID: 29915442      PMCID: PMC5995742          DOI: 10.18999/nagjms.80.2.249

Source DB:  PubMed          Journal:  Nagoya J Med Sci        ISSN: 0027-7622            Impact factor:   1.131


  24 in total

1.  Towards a re-definition of 'cardiac hypertrophy' through a rational characterization of left ventricular phenotypes: a position paper of the Working Group 'Myocardial Function' of the ESC.

Authors:  Ralph Knöll; Guido Iaccarino; Guido Tarone; Denise Hilfiker-Kleiner; Johann Bauersachs; Adelino F Leite-Moreira; Peter H Sugden; Jean-Luc Balligand
Journal:  Eur J Heart Fail       Date:  2011-06-27       Impact factor: 15.534

2.  Regression of left ventricular hypertrophy and microalbuminuria changes during antihypertensive treatment.

Authors:  Enrique Rodilla; Jose Maria Pascual; Jose Antonio Costa; Joaquin Martin; Carmen Gonzalez; Josep Redon
Journal:  J Hypertens       Date:  2013-08       Impact factor: 4.844

3.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study.

Authors:  D Levy; R J Garrison; D D Savage; W B Kannel; W P Castelli
Journal:  N Engl J Med       Date:  1990-05-31       Impact factor: 91.245

4.  Left ventricular hypertrophy determined by Sokolow-Lyon criteria: a different predictor in women than in men?

Authors:  R L Antikainen; T Grodzicki; A J Palmer; D G Beevers; J Webster; C J Bulpitt
Journal:  J Hum Hypertens       Date:  2006-06       Impact factor: 3.012

5.  Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction.

Authors:  Kristian Wachtell; Vittorio Palmieri; Michael H Olsen; Jonathan N Bella; Tapio Aalto; Björn Dahlöf; Eva Gerdts; Jackson T Wright; Vasilios Papademetriou; Carl E Mogensen; Knut Borch-Johnsen; Hans Ibsen; Richard B Devereux
Journal:  Am Heart J       Date:  2002-02       Impact factor: 4.749

6.  Microalbuminuria, renal dysfunction and cardiovascular complication in essential hypertension.

Authors:  G Cerasola; S Cottone; G Mulé; E Nardi; M T Mangano; G Andronico; A Contorno; M Li Vecchi; P Galione; F Renda; G Piazza; V Volpe; A Lisi; L Ferrara; N Panepinto; R Riccobene
Journal:  J Hypertens       Date:  1996-07       Impact factor: 4.844

7.  Left ventricular hypertrophy and microalbuminuria in patients with essential hypertension.

Authors:  Ali Monfared; Arsalan Salari; Fardin Mirbolok; Maryam Momeni; Shora Shafighnia; Maryam Shakiba; Amir Sheikholeslami
Journal:  Iran J Kidney Dis       Date:  2013-05       Impact factor: 0.892

8.  [Left ventricular hypertrophy in the Spanish hypertensive population. The ERIC-HTA study].

Authors:  José V Lozano; Josep Redón; Luis Cea-Calvo; Cristina Fernández-Pérez; Jorge Navarro; Alvaro Bonet; Jorge González-Esteban
Journal:  Rev Esp Cardiol       Date:  2006-02       Impact factor: 4.753

Review 9.  Left ventricular hypertrophy and clinical outcomes in hypertensive patients.

Authors:  Luis M Ruilope; Roland E Schmieder
Journal:  Am J Hypertens       Date:  2008-03-13       Impact factor: 2.689

10.  Relation between diurnal variation of blood pressure and left ventricular mass in a Chinese population.

Authors:  C H Chen; C T Ting; S J Lin; T L Hsu; P Chou; H S Kuo; S P Wang; F C Yin; M S Chang
Journal:  Am J Cardiol       Date:  1995-06-15       Impact factor: 2.778

View more
  1 in total

1.  Anxiety and Depression among Hypertensive Outpatients in Afghanistan: A Cross-Sectional Study in Andkhoy City.

Authors:  Mohammad Shoaib Hamrah; Mohammad Hassan Hamrah; Hideki Ishii; Susumu Suzuki; Mohammad Hussain Hamrah; Ahmad Edris Hamrah; Ahmad Elias Dahi; Kyosuke Takeshita; Maimaiti Yisireyili; Mohammad Hashem Hamrah; Akbar Fotouhi; Junichi Sakamoto; Toyoaki Murohara
Journal:  Int J Hypertens       Date:  2018-08-01       Impact factor: 2.420

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.